Category: ASX Release

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabine Encouraging clinical responses were observed in this very heavily pre-treated AML patient population…

Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML)…

6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before…

23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a number of additional clinicallytranslatable drug combinations…

31 January 2022 – Race Oncology Limited (“Race”) is pleased to announce theappointment of Christina Manfre, as Chief Financial Officer. Christina is employed as a partner at PKF Sydney Pty Ltd and will via PKF provideleadership to Race Oncology’s financial…